Dr. Branimir Sikic, MD

Clinical trial designs for testing biomarker-based persolized therapies

CLINICAL TRIALS, 2012

NFKBIA Deletion in Glioblastomas.

NEW ENGLAND JOURL OF MEDICINE, 2011

A Network Model of a Cooperative Genetic Landscape in Brain Tumors

JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION, 2009

Differential gene expression patterns and interaction networks in BCR-ABL

JOURL OF CLINICAL ONCOLOGY, 2007

Regiol activation of chromosomal arm 7q with

GENES CHROMOSOMES & CANCER, 2006

Phase I study of gefitinib, oxaliplatin

INVESTIGATIOL NEW DRUGS, 2006

Tumor necrosis factor-alpha

JOURL OF CLINICAL ONCOLOGY, 2006

Gene expression profiling differentiates germ cell tumors from other cancers

PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2005

Functiol network alysis reveals extended gliomagenesis pathway maps

CANCER RESEARCH, 2005

Phase II study of gefitinib, fluorouracil

JOURL OF CLINICAL ONCOLOGY, 2005

Modulation of resistance to idarubicin by the cyclosporin PSC 833

Jourl of experimental therapeutics & oncology, 2003

MDR1 activation is the predomint resistance mechanism selected by vinblastine in MES-SA cells

BRITISH JOURL OF CANCER, 2000

Modulation of multidrug resistance: A paradigm for translatiol clinical research

ONCOLOGY-NEW YORK, 1999

Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype

JOURL OF BIOLOGICAL CHEMISTRY, 1997

DECREASED MUTATION-RATE FOR CELLULAR

JOURL OF THE TIOL CANCER INSTITUTE, 1995

MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ALYSIS

JOURL OF THE TIOL CANCER INSTITUTE, 1994

PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE

JOURL OF CLINICAL ONCOLOGY, 1994

MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD

JOURL OF CLINICAL ONCOLOGY, 1993

PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE

JOURL OF CLINICAL ONCOLOGY, 1992

ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYMICS BY CYCLOSPORINE IN A PHASE

JOURL OF CLINICAL ONCOLOGY, 1992

DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ALOG

SCIENCE, 1985

QUANTIFICATION OF BLEOMYCIN PULMORY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT

CANCER RESEARCH, 1978

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3

INVESTIGATIOL NEW DRUGS, 2012

A phase I trial of vandetanib combined with capecitabine

INVESTIGATIOL NEW DRUGS, 2012

Phase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies

INVESTIGATIOL NEW DRUGS, 2011

Phase I and pharmacokinetic study of lexatumumab

ANLS OF ONCOLOGY, 2010

Alysis of phase II studies on targeted agents and subsequent phase III trials

JOURL OF CLINICAL ONCOLOGY, 2008

Predictors for success in a phase III trial

Ueda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., Mon, 2007

Integrated high-resolution genome-wide alysis of gene dosage

Methods in molecular biology (Clifton, N.J.), 2007

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)

ANLS OF ONCOLOGY, 2005

A phase I trial of aprinocarsen (ISIS 3521

INVESTIGATIOL NEW DRUGS, 2005

A phase I trial of oblimersen and gemcitabine in refractory and advanced maligncies

Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzg, 2005

Amplification of whole tumor genomes

JOURL OF MOLECULAR DIAGNOSTICS, 2005

Mitoxantrone, etoposide

JOURL OF CLINICAL ONCOLOGY, 2004

A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kise C alpha

CANCER, 2004

A phase II study of gefitinib in combition with FOLFOX-4

Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J, 2003

Phase I and pharmacokinetic study of BMS-188797, a new taxane alog

CLINICAL CANCER RESEARCH, 2003

Protein expression study of ovarian surface epithelial neoplasms using tissue microarray alysis

Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B., 2003

Rapid determition of PEGylated liposomal doxorubicin

JOURL OF CHROMATOGRAPHY B-ALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND , 2002

A phase I study of ZD 1839 (Iressa) in combition with oxaliplatin

Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., , 2002

Re: Genetic alysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer

JOURL OF THE TIOL CANCER INSTITUTE, 2002

Domint effector genetics in mammalian cells

TURE GENETICS, 2001

Mitoxantrone, etoposide

JOURL OF CLINICAL ONCOLOGY, 2000

Decreased cortisol secretion by adrel gl

ANTI-CANCER DRUGS, 2000

Effect of high-dose cyclosporine on etoposide pharmacodymics in a trial to reverse P-glycoprotein

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000

Phase I study of an antisense oligonucleotide to protein kise C-alpha (ISIS 3521

CLINICAL CANCER RESEARCH, 1999

Mechanisms of action of and resistance to antitubulin agents: Microtubule dymics, drug transport

JOURL OF CLINICAL ONCOLOGY, 1999

Treatment of refractory

BLOOD, 1999

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein

JOURL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998

Pharmacologic approaches to reversing multidrug resistance

SEMIRS IN HEMATOLOGY, 1997

Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine

ANLS OF ONCOLOGY, 1997

Spontaneous overexpression of the long form of the bcl

BRITISH JOURL OF CANCER, 1997

Differential single- versus double

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996

Pharmacological considerations in the modulation of multidrug resistance

EUROPEAN JOURL OF CANCER, 1996

Doxorubicin selection for MDR1

AMERICAN JOURL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1996

INHIBITION OF LYSOSOMAL ACID SPHINGOMYELISE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1995

EVIDENCE FOR TRANSCRIPTIOL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG

MOLECULAR PHARMACOLOGY, 1995

ALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER

INTERTIOL JOURL OF ONCOLOGY, 1994

MULTIDRUG-RESISTANCE IN LYMPHOMAS

JOURL OF CLINICAL ONCOLOGY, 1994

METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A D STRAND BREAKER TO A D CROSS

BRITISH JOURL OF CANCER, 1994

CLINICAL-TRIALS OF MODULATION OF MULTIDRUG

Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., 1993

CHARACTERIZATION OF COVALENT D-BINDING OF MORPHOLINO AND CYANOMORPHOLINO DERIVATIVES OF DOXORUBICIN

JOURL OF THE TIOL CANCER INSTITUTE, 1992

USE OF ETOPOSIDE IN COMBITION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC

EXPERIMENTAL HEMATOLOGY, 1992

EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-R IN A SUBSET OF NORMAL BONE-MARROW CELLS

BRITISH JOURL OF HAEMATOLOGY, 1992

Use of etoposide in combition with cyclosporine

Progress in clinical and biological research, 1992

Clinical trial designs for testing biomarker-based personalized therapies

CLINICAL TRIALS, 2012

NFKBIA Deletion in Glioblastomas.

NEW ENGLAND JOURNAL OF MEDICINE, 2011

Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells

MOLECULAR CANCER THERAPEUTICS, 2010

A Network Model of a Cooperative Genetic Landscape in Brain Tumors

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009

A Phase II Study of Gefitinib, 5-Fluorouracil

CLINICAL CANCER RESEARCH, 2008

Differential gene expression patterns and interaction networks in BCR-ABL

JOURNAL OF CLINICAL ONCOLOGY, 2007

Regional activation of chromosomal arm 7q with

GENES CHROMOSOMES & CANCER, 2006

Phase I study of gefitinib, oxaliplatin

INVESTIGATIONAL NEW DRUGS, 2006

Tumor necrosis factor-alpha

JOURNAL OF CLINICAL ONCOLOGY, 2006

Gene expression profiling differentiates germ cell tumors from other cancers

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2005

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell

CANCER RESEARCH, 2005

Functional network analysis reveals extended gliomagenesis pathway maps

CANCER RESEARCH, 2005

Phase II study of gefitinib, fluorouracil

JOURNAL OF CLINICAL ONCOLOGY, 2005

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors

CANCER RESEARCH, 2005

Gene expression profiles at diagnosis

BLOOD, 2004

CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human

MOLECULAR PHARMACOLOGY, 2004

Modulation of resistance to idarubicin by the cyclosporin PSC 833

Journal of experimental therapeutics & oncology, 2003

Preferential expression of a mutant allele of the amplified MDR1

GENES CHROMOSOMES & CANCER, 2002

MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells

BRITISH JOURNAL OF CANCER, 2000

Loss of cyclosporin

MOLECULAR PHARMACOLOGY, 2000

Modulation of multidrug resistance: A paradigm for translational clinical research

ONCOLOGY-NEW YORK, 1999

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997

Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997

Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel

CANCER RESEARCH, 1996

DECREASED MUTATION-RATE FOR CELLULAR

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995

The reversal of multidrug resistance.

Cancer treatment and research, 1995

PREVALENCE OF MULTIDRUG

CANCER RESEARCH, 1994

MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ANALYSIS

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994

PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE

JOURNAL OF CLINICAL ONCOLOGY, 1994

MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD

JOURNAL OF CLINICAL ONCOLOGY, 1993

PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE

JOURNAL OF CLINICAL ONCOLOGY, 1992

ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS BY CYCLOSPORINE IN A PHASE

JOURNAL OF CLINICAL ONCOLOGY, 1992

MULTIDRUG RESISTANCE

BLOOD, 1991

MULTIDRUG (PLEIOTROPIC) RESISTANCE IN DOXORUBICIN

CANCER RESEARCH, 1985

DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ANALOG

SCIENCE, 1985

DEVELOPMENT AND CHARACTERIZATION OF A HUMAN SARCOMA CELL-LINE, MES-SA, SENSITIVE TO MULTIPLE-DRUGS

CANCER RESEARCH, 1983

IMPROVED THERAPEUTIC INDEX OF BLEOMYCIN WHEN ADMINISTERED BY CONTINUOUS INFUSION IN MICE

CANCER TREATMENT REPORTS, 1978

QUANTIFICATION OF BLEOMYCIN PULMONARY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT

CANCER RESEARCH, 1978

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3

INVESTIGATIONAL NEW DRUGS, 2012

A phase I trial of vandetanib combined with capecitabine

INVESTIGATIONAL NEW DRUGS, 2012

Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine

INVESTIGATIONAL NEW DRUGS, 2011

Phase I Study of Valspodar

PEDIATRIC BLOOD & CANCER, 2010

Phase I and pharmacokinetic study of lexatumumab

ANNALS OF ONCOLOGY, 2010

Analysis of phase II studies on targeted agents and subsequent phase III trials

JOURNAL OF CLINICAL ONCOLOGY, 2008

Predictors for success in a phase III trial

Ueda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., Mon, 2007

Integrated high-resolution genome-wide analysis of gene dosage

Methods in molecular biology (Clifton, N.J.), 2007

Gene expression profiling predicts outcome in de novo acute myeloid leukemia

Lacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., Juric, D., 2006

Differential gene expression patterns and interaction networks in BCR

Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., 2006

A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel

CANCER INVESTIGATION, 2006

Multidrug resistance and stem cells in acute myeloid leukemia

CLINICAL CANCER RESEARCH, 2006

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)

ANNALS OF ONCOLOGY, 2005

Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia

Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu,, 2005

A phase I trial of aprinocarsen (ISIS 3521

INVESTIGATIONAL NEW DRUGS, 2005

Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors

CLINICAL LUNG CANCER, 2005

A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies

Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzg, 2005

Amplification of whole tumor genomes

JOURNAL OF MOLECULAR DIAGNOSTICS, 2005

A method for detecting and correcting feature misidentification on expression microarrays

BMC GENOMICS, 2004

Resistance to microtubule

Bulletin du cancer, 2004

Mitoxantrone, etoposide

JOURNAL OF CLINICAL ONCOLOGY, 2004

Genomics-based hypothesis generation

LANCET ONCOLOGY, 2004

A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha

CANCER, 2004

A phase II study of gefitinib in combination with FOLFOX-4

Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J, 2003

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog

CLINICAL CANCER RESEARCH, 2003

Gene expression patterns in ovarian carcinomas

MOLECULAR BIOLOGY OF THE CELL, 2003

Phase I trial of uracil-ftorafur, leucovorin

BREAST CANCER RESEARCH AND TREATMENT, 2003

Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis

Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B., 2003

Rapid determination of PEGylated liposomal doxorubicin

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL , 2002

A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin

Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., , 2002

Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002

Pharmacokinetic interactions of cyclosporine with etoposide

LEUKEMIA, 2002

The effect of oral valspodar (psc 833), a modulator of multidrug resistance

Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, 2002

Conservation of the class I beta-tubulin gene in human populations

MOLECULAR CANCER THERAPEUTICS, 2002

Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin

CLINICAL CANCER RESEARCH, 2001

A phase I trial of doxorubicin, paclitaxel

Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litc, 2001

Dominant effector genetics in mammalian cells

NATURE GENETICS, 2001

Clinical studies of antisense therapy in cancer

FRONTIERS IN BIOSCIENCE, 2000

Mitoxantrone, etoposide

JOURNAL OF CLINICAL ONCOLOGY, 2000

Decreased cortisol secretion by adrenal gl

ANTI-CANCER DRUGS, 2000

Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000

Treatment of refractory

Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan,, 1999

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521

CLINICAL CANCER RESEARCH, 1999

Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport

JOURNAL OF CLINICAL ONCOLOGY, 1999

Treatment of refractory

BLOOD, 1999

Mitoxantrone, etoposide

Tallman, M. S., Lee, S., Sikic, B. I., Paietta, E., Wiernik, P. H., Be, 1999

Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide

Advani, R., Visani, G., Milligan, D., Saba, H., Tallman, M., Rowe, J. , 1999

New approaches in cancer treatment

Sikic, B. I., 1999

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998

Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998

Pharmacologic approaches to reversing multidrug resistance

SEMINARS IN HEMATOLOGY, 1997

Validation of a limited sampling model to determine etoposide area under the curve

PHARMACOTHERAPY, 1997

Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine

ANNALS OF ONCOLOGY, 1997

Spontaneous overexpression of the long form of the bcl

BRITISH JOURNAL OF CANCER, 1997

Differential single- versus double

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996

Pharmacological considerations in the modulation of multidrug resistance

EUROPEAN JOURNAL OF CANCER, 1996

Doxorubicin selection for MDR1

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1996

Neural network (NN)

Lum, B. L., Synold, T. W., Lane, K., Charnick, S. B., Sikic, B. I., 1996

Differential expression of tubulin isotypes during the cell cycle

CELL MOTILITY AND THE CYTOSKELETON, 1996

Effect of different mathematical methods on etoposide area under the curve estimations

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996

GLUTATHIONE-S-TRANSFERASE-PI, GLUTATHIONE-S-TRANSFERASE-ALPHA

LEUKEMIA, 1995

CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS

ANTI-CANCER DRUGS, 1995

INHIBITION OF LYSOSOMAL ACID SPHINGOMYELINASE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1995

Drug resistance in clinical oncology and hematology. Introduction.

Hematology/oncology clinics of North America, 1995

CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1995

Novel mechanism of resistance to paclitaxel (Taxol(R))

ONCOLOGY RESEARCH, 1995

EVIDENCE FOR TRANSCRIPTIONAL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG

MOLECULAR PHARMACOLOGY, 1995

ANALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER

INTERNATIONAL JOURNAL OF ONCOLOGY, 1994

MULTIDRUG-RESISTANCE IN LYMPHOMAS

JOURNAL OF CLINICAL ONCOLOGY, 1994

VOLUME-ACTIVATED CHLORIDE CURRENT IS NOT RELATED TO P-GLYCOPROTEIN OVEREXPRESSION

CANCER RESEARCH, 1994

METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A DNA STRAND BREAKER TO A DNA CROSS

BRITISH JOURNAL OF CANCER, 1994

MDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS

LEUKEMIA, 1994

CYCLOSPORINE A AND CYCLOSPORINE SDZ PSC 833 ENHANCE ANTI-CD5 RICIN A

BLOOD, 1994

Clinical reversal of multidrug resistance.

Cancer treatment and research, 1994

REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY

LEYLANDJONES, B., Dalton, W., Fisher, G. A., Sikic, B. I., 1993

CLINICAL-TRIALS OF MODULATION OF MULTIDRUG

Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., 1993

EFFECTS OF THE METHOXYMORPHOLINO DERIVATIVE OF DOXORUBICIN AND ITS BIOACTIVATED FORM VERSUS

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993

MOLECULAR TARGETS IN ONCOLOGY - IMPLICATIONS OF THE MULTIDRUG RESISTANCE GENE

PHARMACOTHERAPY, 1993

THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD

Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., 1993

CHARACTERIZATION OF COVALENT DNA

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992

USE OF ETOPOSIDE IN COMBINATION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC

EXPERIMENTAL HEMATOLOGY, 1992

ROLE OF CYTOCHROME-P

CANCER RESEARCH, 1992

EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-RNA IN A SUBSET OF NORMAL BONE-MARROW CELLS

BRITISH JOURNAL OF HAEMATOLOGY, 1992

Use of etoposide in combination with cyclosporine

Progress in clinical and biological research, 1992

COMBINED CHEMOTHERAPY AND RADIOTHERAPY FOR ADVANCED-STAGE CARCINOMAS OF THE CERVIX

Sikic, B. I., 1992

Purging multidrug resistant cells from bone marrow.

Progress in clinical and biological research